RNA m6A Modification in Immunocytes and DNA Repair: The Biological Functions and Prospects in Clinical Application.

As the most prevalent internal modification in mRNA, N 6-methyladenosine (m6A) plays broad biological functions via fine-tuning gene expression at the post-transcription level. Such modifications are deposited by methyltransferases (i.e., m6A Writers), removed by demethylases (i.e., m6A Erasers), and recognized by m6A binding proteins (i.e., m6A Readers). The m6A decorations regulate the stability, splicing, translocation, and translation efficiency of mRNAs, and exert crucial effects on proliferation, differentiation, and immunologic functions of immunocytes, such as T lymphocyte, B lymphocyte, dendritic cell (DC), and macrophage. Recent studies have revealed the association of dysregulated m6A modification machinery with various types of diseases, including AIDS, cancer, autoimmune disease, and atherosclerosis. Given the crucial roles of m6A modification in activating immunocytes and promoting DNA repair in cells under physiological or pathological states, targeting dysregulated m6A machinery holds therapeutic potential in clinical application. Here, we summarize the biological functions of m6A machinery in immunocytes and the potential clinical applications via targeting m6A machinery.

Introduction

While RNA modification was first identified in 1970s, it becomes a research focus in recent years. It broadly exists in different species, including fungi (Bodi et al., 2015), plants (Yue et al., 2019), and animals (Yoon et al., 2017; Xia et al., 2018). During the past decades, researchers have found that RNA methylation is a widespread modification in coding sequence and non-coding sequence (Huang et al., 2020), most of which are located at the amine group outside ring, special nitrogen and carbon positions of purine and pyrimidine, and the oxygen atom of the 2′-OH moiety (Liu and Jia, 2014). If classified by the modified position, RNA methylation mainly consists of N6-methyladenosine (m6A), 5-methylcytosine (m5C), N7-methylguanosine (m7G), etc., among which m7G cap at the 5′end of RNA sequence has been rigorously studied for decades (Devarkar et al., 2016; Pandolfini et al., 2019). However, m6A modification, representing the most abundant modification, needs further study.

As reported, m6A modifications are localized in the conversed DRACH motifs (D = G/A/U, R = G/A, H = A/U/C). The distribution of m6A is usually in the coding and 3′ untranslated regions, especially enriched in the upstream of stop codon in mRNA (Roundtree et al., 2017). Recent researches find that m6A modification is also an important biological mark of endogenous circular RNA (circRNA) (Chen et al., 2019). Moreover, m6A modification in lncRNA can regulate the efficiency of glycolysis (Liu J et al., 2019) or promote oncogenesis (Chen et al., 2020). Since m6A modification is dynamic and reversible, the biological function and molecular mechanism of m6A modification have become a research hotspot in many medical fields.

Writers, Erasers, and Readers

The most momentous breakthrough in this field is the discovery of the m6A machinery involved in m6A modification, including “Writers,” “Erasers” and “Readers,” performing the function of methyltransferase, demethylase, and recognizing the m6A structure, respectively. They dynamically regulate the homeostasis of m6A and its functions in cells.

Writers

With the function of forming m6A structure, “Writers” protein is a 1 MDa complex composed of multiple subunits, containing Methyltransferase like-3 (METTL3) (Liu et al., 2014), Methyltransferase like-14 (METTL14) (Weng et al., 2018), Wilm’s Tumor 1-associating protein (WTAP) (Ping et al., 2014; Sorci et al., 2018), etc. METTL3 is responsible for catalyzing the transfer of methyl group with the support of S-adenosyl-methionine (SAM) in many types of RNA including mRNA and miRNA, while METTL14 is a catalytic cofactor capable of recognizing and binding the target mRNA. WTAP is in charge of recruiting the targeting RNA and locating the METTL3/METTL14/WTAP complex into the nuclear speckles, which is relevant to the prognosis and cisplatin resistance (Ma et al., 2021) of cancer and the infiltration of T lymphocyte within tumors (Li H et al., 2020). New subunits, termed RBM15/RBM15B (Knuckles et al., 2018), KIAA1429 (Lan et al., 2019), ZFP217 (Song et al., 2019), and ZC3H3 (Silla et al., 2020), have been identified, and their functions involve in the recruitment, m6A modification of mRNA or lncRNA, and regulation of the m6A catalytic efficiency. Different types of “Writers” may interact with each other, as a result of which may influence the progression of some diseases such as colorectal cancer (Chen H et al., 2021).

Erasers

The m6A structure can be erased by the “Erasers” protein. Fat mass and obesity-associated protein (FTO) (Jia et al., 2011) was supposed to be the first demethylase discovered, whose existence confirmed the reversibility of m6A modification. FTO and the second identified “Erasers” called AlkB Homolog 5 (ALKBH5) (Zheng et al., 2013) jointly counter the m6A modification of “Writers,” thus maintaining the homeostasis of m6A level in cells, whereas the distribution of the two proteins are tissue-specific. The amino acid sequence HXDXnH and RXXXXXR (X = any amino acid) with demethylase activity are contained in their mutual AlkB domain. Both of them remove the m6A methylation from mRNA with the Fe (II)/α-ketoglutarate-dependent dioxygenase (Fedeles et al., 2015). The demonstration of “Writers” and “Erasers” initiates a new branch, namely, m6A research, in the field of epigenetics. Recent studies on ALKBH5 gradually elucidate its multiple functions in disease progressing and therapeutic efficacy, including CD4+ T cell pathogenicity in autoimmunity (Zhou et al., 2021), anti PD-1 response in tumor treatment (Li N et al., 2020), glucocorticoid resistance in T-cell acute lymphoblastic leukemia cell treatment (Gong et al., 2021), etc.

Readers

The level of m6A in cells is dynamically modulated by “Writers” and “Erasers,” while “Readers” can recognize the m6A structure and regulate the subsequent cell processes such as translation and stability of mRNA. The YTH domain-containing family is the first confirmed component of “Readers,” characterized by the YTH domain at C terminus. YTHDF1∼3 and YTHDC1∼2 (Kasowitz et al., 2018; Zhou et al., 2020) are identified as m6A binding proteins, among which researches concerning YTHDF are more detailed. Generally speaking, the aforementioned m6A “Readers” proteins have the same function of binding the m6A-modified mRNA with the consensus YTH domain at C terminus, while YTHDF1 promote translation by binding the m6A at translation initiation site (Zhuang et al., 2019); YTHDF2, characterized by the P/Q/N-rich domain at N terminus, recruits the CCR4-NOT deadenylase complex and brings the target mRNA to cytoplasmic P bodies (Du et al., 2016), resulting in the destabilization of mRNA (Paris et al., 2019); YTHDF3 is also related to mRNA decay, but it is regarded to have a synergistic effect on YTHDF1 and YTHDF2 (Ni et al., 2019). In contrast to YTHDF, additional Readers such as insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) (Hanniford et al., 2020) can uniquely stabilize the target mRNA, while the eukaryotic initiation factor 3 (eIF3) (Meyer et al., 2015; Wolf et al., 2020) can promote cap-independent translation of mRNA with 5′-UTR m6A modified. Moreover, other m6A Readers like ELAVL1 (Zhang et al., 2017) are being studied recently.

Roles of m6A Modification in Immunocytes

Immunocytes play a crucial role in a variety of bioprocesses, such as recognizing and presenting the pathogen and immune response, whose depletion or dysfunction is the important pathological basis of tumorigenesis, viral infection, and autoimmune diseases, etc. Previous researches focused on the function of m6A in cancer cells, including endometrial cancer (Liu et al., 2018), breast cancer (Cai et al., 2018), bladder cancer (Cheng et al., 2019), hepatocellular cancer (Zhao X et al., 2018), nasopharyngeal cancer (Zhang et al., 2018), glioblastoma stem cells (Cui et al., 2017), acute myeloid leukemia (Cui et al., 2017), etc. Nevertheless, recent m6A researches on T lymphocyte, B lymphocyte, DC, and macrophage broaden our cognition towards the human immune system, which are the latest achievements of m6A modification.

T Lymphocyte

T lymphocyte is the executant of human adaptive immune system, which is related to antitumor immunity and autoimmune diseases. Furthermore, T lymphocyte is likely to have interaction with neural stem cells, thus inhibiting its proliferation and resulting in age-related brain disease (Dulken et al., 2019); the abnormal level of m5C, another form of RNA methylation, in CD4+ T lymphocytes may have a potential link with the pathogenesis of systemic lupus erythematosus (SLE) (Guo G et al., 2020). According to the differences in function and phenotype, T lymphocyte can be divided into subtypes including naïve T cell (Tn), cytotoxic T cell, regulatory T cell (Treg), helper T cell (Th), etc., which is mainly driven by the stimulation of inflammation factor such as interleukin (IL) and tumor necrosis factor (TNF). Recently, bile acid has been proved to be an accessional regulator of Th17 (Hang et al., 2019) and Treg differentiation. The newly discovered subtype termed exhausted T cell (Tex) along with its key transcription factor called thymocyte selection-associated high mobility group box (TOX) (Scott et al., 2019) is a breakthrough in antitumor study, although the connection between Tex and m6A remains to be explored.

Studies focusing on m6A in T lymphocyte mark the initiation of m6A study in adaptive immune field. Li H-B et al. (2017) found that 5 weeks after transplant of wild type Tn, Rag−/− mice develop colitis due to the differentiation of Tn into effector T cell, whereas Rag−/− mice with Mettl3−/− transplanted exhibit no sign of similar symptoms and no T cell infiltration or inflammation inside spleen and colon can be observed. FACS shows the dysfunction of Mettl3−/− Tn differentiation. Molecular biology studies indicate that Soc1, Soc3, and Cish mRNA are stabilized owing to the lack of m6A modification; afterwards, elevated SOCS protein inhibits the phosphorylation of STAT5, then the IL-7 mediated JAK-STAT5 pathway will be blocked, and thus the differentiation of Tn is suffocated. However, because Mettl3−/− strengthen ERK and APK pathway simultaneously, no obvious increase in T cell apoptosis can be observed. Follow-up study (Tong et al., 2018) found that Tn homeostasis of Mettl3f/f; CD4-Cre mice can be destroyed and have colitis 3 months after being born, because Treg’s suppression of effector T cell is faulted. During this process, genetic depletion of Mettl3 reduces the m6A modification of Socs mRNA, then stabilizes mRNA, and upregulates its expression. High level SOCS protein inhibits IL-2-STAT5 pathway, resulting in the dysfunction of Treg. Additionally, it is demonstrated that Treg can strengthen type-II DC’s ability of presenting antigen (Binnewies et al., 2019), enhance antitumor response, and improve prognosis of checkpoint blockade such as PD-1 block immunotherapy (shown in Figure 1).

FIGURE 1

m6A decoration contributes to the regulation of Tn differentiation and Treg function both through JAK-STAT5 pathway. m6A modifications in Soc1, Soc3, and Cish mRNA accelerate their degradation, thus decreasing the expression of SOCS. As a consequence, through the JAK/STAT5 pathway, IL-7 induced differentiation of Tn and IL-2 induced suppressive function of Treg are both influenced afterwards.

Another study (Lu et al., 2020) unveils the function of Mettl14 in T lymphocytes. In this research, CD4-Cre+/Tg Mettl14FL/FL conditional knockout mice have found to develop spontaneous colitis due to the increased level in Th1 cytokines, such as IFN-γ and TNF-α. Follow-up studies show that RORγt expression in Mettl14 deficient Tregs is downregulated compared to the wild-type Tregs and the induction efficacy of Mettl14 deficient Tn to iTreg is obviously impaired. As a consequence, both the reduction of iTregs, whose function has reported to be controlling the experimental colitis, and the dysfunctional Mettl14 deficient Tregs lead to the development of spontaneous colitis. With the function of METTL3 in T follicular helper cell differentiation being clarified recently (Yao et al., 2021), plenty of evidences have persuade us that m6A may play an irreplaceable role in all subtypes of T cells.

Furthermore, in acute myeloid leukemia (AML), FTO inhibition can lead to downregulation of leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), render AML cells vulnerable to activated T cells, and simultaneously overcome hypomethylating agent (HMA)-induced immune evasion. FTO’s function in anti-tumor immunity, especially its function in T cells, can be a promising therapeutic strategy in the field of m6A research (Su et al., 2020).

In addition, when CD4+ T cell is infected by the Human Immunodeficiency Virus (HIV), both HIV RNA and intrinsic RNA will be obviously increased (Lichinchi et al., 2016) independent of virus replication. Only gp120 will upregulate the level of m6A without influencing the expression of Writers and Erasers (Tirumuru and Wu, 2019). The m6A modification position of HIV RNA mainly distributes at 3′-UTR (Kennedy et al., 2016), which is directly involved in the regulation of viral mRNA nuclear export and protein synthesis. The m6A modification machinery, such as YTHDF (Tirumuru et al., 2016), METTL3/METTL14, and ALKBH5 (Lichinchi et al., 2016), act as a crucial regulator of this process. The m6A modification of HIV RNA will affect the expression of viral proteins including p55 (the product of gene gag) and Rev, consequently impacting the viral infectivity and replication, while suppressing the expression of IFN-I in monocytic cells and macrophages at the same time (Chen S et al., 2021). Therefore, antibodies neutralizing gp120 or CD4+ probably have the potential to counter HIV. Besides, Fu et al. (2019) for the first time applied HIV transgenic rats for m6A research and elucidated the role of m6A modification in mRNA in chronic HIV diseases, especially neurologic disorder (shown in Figure 2).

FIGURE 2

m6A-associated proteins in HIV-infected T lymphocytes regulate the expression of HIV mRNA. METTL3/METTL14 can install m6A decoration on HIV mRNA, while ALKBH5 can remove such modification. YTHDF1-3 recognize the m6A structure and influence the expression of HIV mRNA such as Rev and p55. With the support of Rev, HIV mRNA modified by m6A can export nucleus more easily, which promote the replication of HIV.

In conclusion, the effect of YTHDF2 on virus remains to be ascertained or can be bidirectional (Toro-Ascuy et al., 2016; Lu W et al., 2018); YTHDF3 weakens the viral infectivity and inhibits the viral replication. Uniquely, YTHDF3 can be incorporated into the virion and still keep its antiviral activation, but the HIV protease can cleave the virion containing YTHDF3. This mechanism prevents HIV from being killed thoroughly and provides a new thought for HIV treatment (Jurczyszak et al., 2020).

All the researches above reveal that m6A along with associated protein can alter the stability of mRNA and regulate nuclear export and translation of mRNA, thus influencing the bioprocess of T cell with different phenotype and promoting the progression of certain diseases.

B Lymphocyte

B lymphocyte is involved in the humoral immunity by producing antibodies. Applying bioengineering technology to design special improbable immunogen can induce the synthesis of antibodies with high affinity, which have the potential to treat virus infection, such as HIV (Saunders et al., 2019). A recent clinical study suggests that m6A modification is closely related to the oncogenesis and progress of mantle cell lymphoma (Zhang W et al., 2019). Mantle cell lymphocyte is a kind of non-hodgkin B cell lymphoma characterized by aggressive phenotype and rapid rate of progression. After analysis of 123 samples of clinical patients, the hazard ratios of YTHDF3, METTL3, FTO, METTL14, ALKBH5, YTHDF2, and WTAP are below 1, while those of YTHDF1, KIAA1429, and ELAVL1 are above 1, among which the maximum is ELAVL while the minimum is YTHDF3, implying that ELAVL and YTHDF3 might be the most important regulators of mantle cell lymphoma. Moreover, “m6A index” is proposed to evaluate the prognosis of patients. Without much available biology research data, this statistical study directs a path for the following m6A research concerning B lymphocyte.

Recent studies have shown that the deletion of Mettl14 can decrease the m6A level in developing B cells and inhibit some important processes, such as the IL-7-induced Pro-B cell proliferation and the transition to the Large Pre-B Stage, which depends on the function of YTHDF2 (Zheng et al., 2020) (shown in Figure 3). However, the Large-Pre-B-to-Small-Pre-B Transition depends on METTL14, but is independent of YTHDF1 or YTHDF2 (shown in Figure 3).

FIGURE 3

METTL3/METTL14 complex and YTHDF1 is necessary for the early development of B lymphocytes. METTL14 plays an unreplaceable role in the IL-7 induced Pro-B lymphocyte proliferation, Pro-B-to-Large-Pre-B transition, and Large-Pre-B-to-Small-Pre-B transition. YTHDF2 will recognize the m6A modification afterwards and decrease the transcripts as a result, which promote early B lymphocyte development. Notably, YTHDF2 only facilitate in the first two process. The Large-Pre-B-to Small-Pre-B Transition is independent of YTHDF1 or YTHDF2.

The pathogenesis of diffuse large B-cell lymphoma (DLBCL), which is the most common subtype of lymphoma derived from B lymphocytes, has been illustrated to have a link with upregulated METTL3 and the m6A level of the mRNA of pigment epithelium-derived factor (Cheng et al., 2020), while PIWI-interacting RNAs have been identified to function in this process recently (Han et al., 2021). The association between B lymphocytes and other m6A methylation-related proteins remains to be explored.

Besides, Kaposi’s sarcoma (KS) is evidently associated with infection of HIV and Kaposi’s sarcoma-associated herpesvirus (KSHV). KSHV shows strong lymphotropic and invades B cells in the circulation (Myoung and Ganem, 2011). During this process, m6A Reader protein YTHDF2 plays a positive role in KSHV replication (Hesser et al., 2018). However, inconsistent with its feature in vivo, KSHV exhibits weaken infectivity and proliferation in B cells lines in vitro, so the role of m6A and associated protein in the oncogenesis of KS remains to be explored.

DC

As the bridge between the innate and adaptive immune, DCs function as antigen-presenting cells and can also produce VEGF-α for the recruitment of neutrophil to control cutaneous bacterial infections (Janela et al., 2019). Therefore, DCs play a core role in the eradication of pathogen and inducement of immune tolerance. It has been evidenced that the dysfunction of DC activation is involved in the progression of multiple inflammation, cancer, and autoimmune diseases. Tyrosine kinase AXL can induce the expression of PD-1. IFN-γ and IL-4 can respectively promote and inhibit the production of IL-12; thus, blockade of IL-4 receptor can strengthen antitumor response by expanding the infiltration of T lymphocyte at tumor position (Maier et al., 2020). Though the association between the suppression of DCs and extracellular m6A-modified RNA has been confirmed for decades (Karikó et al., 2005), studies concerning m6A in DCs are still at its infant stage.

Wang H et al. (2019) found that total level of m6A in DCs is increasing parallel with its maturation. The distribution of m6A is mainly located in NLR, TNF, and NF-κB pathways, which are responsible for the induction of co-stimulatory factors and pro-inflammation factors which promote maturation of DCs. METTL3 was involved in this physiological process. Distinct from most of the previous laboratory findings, the fundamental mechanism is the upregulation of translation efficiency, but not the stability of mRNA (Wang H et al., 2019) (shown in Figure 4).

FIGURE 4

METTL3 up-regulates the expression of CD40, CD80, and IL-12, which promote the maturation of immature DC. In the end, its ability of presenting antigen and interaction with T lymphocytes are strengthened.

Han et al. (2019) discovered the connection between upregulated translation and YTHDF1. The depletion of YTHDF1 in DCs will limit the expression of lysosomal protease, which decelerates the degradation of antigen, thus improving DCs’ ability of presenting antigen and activating CD8+ T cell. This suggests a new mechanism of immune escape as well as an important reason for weak antitumor immune response in certain clinical cases (Han et al., 2019) (shown in Figure 5).

FIGURE 5

YTHDF1 increases the level of cathepsin in mature DCs, which accelerates the cleavage of antigens in phagosome, making DCs’ ability of presenting antigen impaired.

Macrophage

Macrophage is a kind of innate immune cell dwelling in various tissues with multiple subtypes, which can be classified into classically activated macrophages (M1) and alternatively activated macrophages (M2). Early researches have implied the possibility of m6A weakening immune response (Durbin et al., 2016). However, recent researches indicate that m6A modification plays an important role in antivirus, negative feedback control of macrophage activation (Du et al., 2020), and the polarization of macrophages. Roles of m6A Writers, Erasers, and Readers in macrophages are summarized in Table 1.

TABLE 1

Roles of m6A Writers, Erasers, and Readers in macrophages.

m6A regulator	Cell subtype	Target genes	Biological function
Writers
METTL3	M1	STAT1	Promote polarization
	M2	STAT1	Inhibit polarization
	M1/M2	Cgas, Ifi16, Sting, hnRNPA2B1	Increase the production of IFN-β Amplify the immune response to DNA virus
		Irakm	Promote activation
METTL14	M1/M2	Ebi3	suppress CD8+ T cell dysfunction and tumor growth
Erasers
FTO	M1	STAT1	Promote polarization
	M2	STAT6, PPAR-γ
ALKBH5	M1/M2	Mavs, Traf3, Traf6	Inhibit translation and production of IFN
Readers
YTHDF2	M1/M2	STAT1, PPAR-γ	Impede macrophage activation
		MAP2K4, MAP4K4	Inhibit the expression of pro-inflammatory cytokine and inflammatory response
YTHDF3		FOX O 3	Impede the expression of IFN-stimulated genes and immunity response to VSV
IGF2BP2		TSC1, PPAR-γ	regulate macrophage phenotypic activation and inflammatory diseases

In detail, “Writers” METTL3 catalyzes the m6A methylation at coding sequence (CDS) and 3′-UTR of STAT1 mRNA, facilitating the polarization of M1, but having opposite impact on M2 (Liu Y et al., 2019). Another study has also illustrated METTL3’s function in promoting M1 differentiation, which afterwards benefits bone marrow mesenchymal stem cells (Lei et al., 2021). Moreover, METTL3 can methylate hnRNPA2B1 and Cgas, Ifi16, and Sting mRNA simultaneously, and then the affinity of hnRNPA2B1 to three mRNA above is improved, which ultimately increases the production of IFN-β and amplifies the immune response to DNA virus (Wang L et al., 2019). In addition, METTL3 deficiency have proved to impede the activation of macrophages through TLR4 signaling pathway by stabilizing Irakm transcripts (Tong et al., 2021). As for METTL14, there is also indirect evidence indicating its function in suppressing CD8+ T cell dysfunction and tumor growth (Dong et al., 2021).

After knockout of “Erasers” FTO, the polarization of both M1 and M2 can be inhibited, during which the expression of STAT1 in M1 was decreased, while the degradation of STAT6 and PPAR-γ mRNA is increased (Gu et al., 2020). Furthermore, ALKBH5 demethylate DDX46-binded Mavs, Traf3, and Traf6 mRNAs, leading to the retention of these mRNAs inside nuclear, indirectly inhibiting translation and reducing the production of IFN. In the end, antiviral activation of macrophages is weakened (Zheng et al., 2017).

Knockdown of “Readers” YTHDF2 can stimulate the expression of STAT1 (Huangfu et al., 2020) and PPAR-γ mRNA (Gu et al., 2020), while forced expression of YTHDF2 could destabilize MAP2K4 and MAP4K4 mRNA and activate the NF-κB and MAPK pathway (Yu et al., 2019), which will facilitate LPS-induced osteoclastogenesis and inflammatory response (Fang et al., 2021). YTHDF3 was regarded as a negative regulator of antivirus. With the assistance of PABP1 and elF4G2, YTHDF3 can bind the translation initiation site of FOXO3 mRNA and promote translation. As a result, the expression of IFN-stimulated genes is inhibited, which weakens the immunity response to Vesicular stomatitis virus (VSV) (Zhang Y et al., 2019). Moreover, another reader IGF2BP2 has also proved to be associated with the phenotypic activation of macrophage (Wang X et al., 2021).

Researches focusing on m6A modification in macrophages reveal its association with some diseases. The occurrence of atherosclerosis (AS) has proved to be linked with m6A modification. During this progress, ox-LDL induces the expression of DDX5 in macrophages and limits the function of METTL3 which transfers the methyl group to macrophages scavenger receptor A (MSR1) mRNA. Ultimately, MSR1 mRNA is stabilized, and more MSR1 is synthesized. Uptake of more lipids further facilitates the formation of foam cells, resulting in the progression of AS (Zhao W et al., 2018). In another study, Zhang X et al. (2021) has also identified the function of METTL3 in promoting ox-LDL-induced inflammation and mitochondrial dysfunction by methylating peroxisome proliferator-activated receptor-γ coactivator 1-alpha (PGC-1α) mRNA with the assistance of YTHDF2. Intriguingly, m5C, another form of RNA methylation, can deteriorate AS induced by hyper-homocysteinemia (Wang et al., 2017), while acute coronary syndrome, whose main pathological basis is AS, is also related to the m6A modification of circ-0029589 in macrophage (Guo M et al., 2020).

The dysfunction of m6A in macrophages is also a pathogenesis factor of autoimmune diseases. Wang J et al. (2019) found that in patients with rheumatoid arthritis, METTL3 in macrophages is obviously improved and positively associated with CRP and ESR. Moreover, lipopolysaccharide (LPS) can stimulate the expression of METTL3 in macrophages and then slack the immune response to inflammation through NF-κB pathway (Wang J et al., 2019). Other autoimmune diseases such as osteoarthritis (Liu Q et al., 2019) and SLE (Li et al., 2018) show possibility of having connection with m6A dysfunction in macrophages.

The Application of m6A Modification and its Development Prospect

Given the identification of aberrant m6A modification in various diseases, targeting m6A machinery in specific cells can be regarded as a new treatment for viral infection, cancer, and autoimmune diseases. However, changes in m6A levels in different diseases are lack of consistency, so treatment targeting m6A should be supposed to modulating m6A level to normal level, instead of simply accelerating or decelerating m6A modification (Wang et al., 2018).

m6A-Associated Proteins Modulating DNA Repair

Plenty of researches have confirmed the correlation between m6A and DNA repair in different situations. Zhang et al. have reported the METTL3-m6A-YTHDC1 axis which promotes the double-strand breaks by modulating DNA-RNA hybrid accumulation (Zhang et al., 2020). Other researches indicate that accumulation of the three-stranded R-loops, formed by RNA: DNA hybrid and single stranded DNA, is regulated by YTHDF2 (Abakir et al., 2020), METTL3, and tonicity-responsive enhancer binding protein (TonEBP) (Kang et al., 2021). More surprisingly, the arginine substrates of METTL14 itself at intrinsically disordered C terminus can also be methylated. It proved to be an initial signal of interaction between METTL14 and RNA polymerase II, which will afterwards implement the m6A modification of target mRNA. Subsequent studies have confirmed that METTL14 arginine methylation is associated with the enhanced translation of DNA repair genes (Wang Z et al., 2021). Recent studies even clarified the correlation between DNA damage repair and m6A-modified retrotransposable element (RTE) RNAs, in which intronic Long Interspersed Element-1 (LINE-1) interacts with the hosting gene transcription, resulting in the downregulation of its expression (Xiong et al., 2021). KIAA1429 was also recently discovered to have close links with the modulation of response to cisplatin in germ cell tumor by interfering with DNA damage response (Miranda-Gonçalves et al., 2021).

As for Erasers, the homologs of AlkB (ALKBHs), which originally function as repair proteins in E. coli, are also important regulators of DNA repair and m6A modification at the same time in mammalian cells (Müller et al., 2017; Müller et al., 2018). Recently, the ERK/JNK/ALKBH5-PTMs/m6A axis has been reported to participate in the regulation of ROS-induced DNA damage response, in which progress IGF2BP also plays a part in extending mRNA half time (Yu et al., 2021). METTL3 and FTO can jointly regulate the m6A modification in RNA at DNA damage sites induced by ultraviolet. The function of DNA polymerase κ (Pol κ), which is the key DNA repair enzyme, require the catalytic activity of METTL3, implying the m6A modification directs the recruitment of Pol κ to the DNA damage sites (Xiang et al., 2017). Furthermore, METTL14 has proved to play a tumor-suppressive role in ultraviolet-induced skin tumorigenesis (Yang et al., 2021). All the m6A-associated proteins which regulate DNA repair are summarized in Table 2.

TABLE 2

m6A-associated proteins in DNA repair.

m6A regulator	Biological function
Writers
METTL3	Modulate DNA-RNA hybrid accumulation
	Regulate accumulation of the three-stranded R-loops
	Regulate the m6A modification in ultraviolet-induced DNA damage
	Direct the recruitment of Pol κ to the DNA damage sites
METTL14	Enhance translation of DNA repair genes
	Suppress ultraviolet-induced skin tumorigenesis
KIAA1429	Interfere with DNA damage response in cisplatin-treated germ cell tumor
Erasers
FTO	Regulate the m6A modification in ultraviolet-induced DNA damage
ALKBH5	Regulate ROS-induced DNA damage response
Readers
YTHDC1	Modulate DNA-RNA hybrid accumulation
YTHDF2	Regulate accumulation of the three-stranded R-loops
IGF2BP2	Extend mRNA half time in ROS-induced DNA damage response

In conclusion, since m6A, along with its associated proteins, plays an important role in the pathogenesis and facilitating DNA repair, attaching m6A-targeted therapy to traditional chemo- or radiotherapy may improve the prognosis of some diseases such as carcinoma through two mechanisms.

Medication Targeting m6A

Abnormally elevated m6A level is the feature of most malignant tumor, so developing new drugs inhibiting m6A modification is the most fundamental idea to treat these diseases. Actually, this kind of drugs has been developed for decades. 3-Deaza-Adenosine (DAA) with its analogue can block S-adenosylhomocysteine (SAH) hydrolase, which results in the accumulation of SAH and feedback suppression of SAM (Chiang, 1998). So DAA can indirectly inhibit the m6A modification of mRNA. However, since DAA can suppress the m6A modification in many physiological or pathological processes, there will be many unexpected side effects, such as the prevention of T lymphocyte activation, hypotensive effect, and activation of gene expression. At present, DAA is mainly used for the treatment of AIDS (Kennedy et al., 2016).

Moreover, some diseases like acute myeloid leukemia (AML) are characterized by the aberrant decrease of m6A (Li Z et al., 2017). Rhein (Chen et al., 2012), curcumin (Lu N et al., 2018), meclofenamic acid (Huang et al., 2015), and Saikosaponin-D (Sun et al., 2021) can inhibit the function of FTO by binding the active site of FTO or m6A position of mRNA. Two emerging small molecules targeting FTO demethylase called FB32 and FB32-2, which can dramatically inhibit the progression of AML cells in vitro and in vivo, have been developed recently (Huang et al., 2019). Coupled with the latest advancement called STM2457, which is a highly potent and selective first-in-class catalytic inhibitor of METTL3 (Yankova et al., 2021), we can foresee that the era of treating AML or other diseases featured by m6A level unbalance using m6A-targeted method is coming.

Immunotherapy Targeting m6A

Although solid researches data is unavailable, the regulatory function of m6A modification to immunocytes makes it possible for m6A to be a new target for immunotherapy. It has been demonstrated that m6A is a regulator of Tn differentiation, T lymphocyte homeostasis (Li H-B et al., 2017), and suppressive function of Tregs (Tong et al., 2018). Recent studies have found that loss of METTL3 in myeloid cells reprograms the macrophages and increases Treg infiltration into tumors by influencing the YTHDF1-mediated translation of SPRED2 (Yin et al., 2021). Therefore, inhibiting mRNA m6A modification of Tregs at tumor site or myeloid cells can motivate the antitumor activation of CD8+ T cell, which can be a promising immunotherapy. Meanwhile, inhibiting mRNA m6A modification in Tn can reduce the formation of effector T cell, which is helpful for the treatment for autoimmune diseases. Furthermore, regulating the expression of METTL3 (Wang H et al., 2019) and YTHDF1 to a suitable level can improve DCs’ ability of presenting tumor neoantigen. More importantly, depletion of YTHDF1 and blockade of checkpoint have a synergistic effect on strengthening antitumor immunity (Han et al., 2019), and ALKBH5 (Li N et al., 2020) and METTL3/14 (Wang et al., 2020) have also proved to regulate anti PD-1 response. So as for patients resistant to the PD-1 immunotherapy, targeting m6A can be a new alternative treatment. Since m6A decoration of viral double-stranded RNA can also downregulate the innate sensing pathway of antiviral response (Qiu et al., 2021), immunotherapy targeting m6A is bound to be a promising therapy for various diseases including viral infections, autoimmune disorders, cancers, etc.

Discussion

As the most abundant post-transcriptional mRNA modification in mammals, m6A is involved in the occurrence of several diseases. Recently, an enormous amount of m6A related studies in immunocytes highlight the fact that targeting m6A can be a promising new treatment strategy for viral infection, cancer, and autoimmune diseases. However, in different cell lines, diseases, even different types of the same diseases, the changes of m6A level, as well as functions of three m6A-associated enzymes lack consistency. Moreover, m6A modification is widely involved in a variety of cellular processes and medication targeting m6A is not selective. All these reasons indicate that clinical treatment via targeting m6A modification may be not safe enough. Thus, there is unmet need to develop more sophisticated techniques for m6A detection (Dai et al., 2018; Castellanos-Rubio et al., 2019). Moreover, detailed studies on disease mechanisms are required to realize the clinical application of m6A-targeting treatment. Pharmaceutical researches on drugs with high selectivity or combination of existing drugs and targeted drug delivery system can also promote the accurate treatment of diseases through the m6A-targeting method. Some recent experimental results have indicated the promising prospects of this field (Zhu et al., 2021). Last but not least, m6A modification is supposed to be highly relevant to gut microbiota (Jabs et al., 2020), heat shock proteins (Feng et al., 2020), sepsis (Sun et al., 2020; Xing et al., 2021), and pulmonary hypertension (Pan et al., 2020) and even peripheral nerve injury (Zhang L et al., 2021). These studies can provide valuable experimental basis for development of new treatments.